Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ABBV-253 in advanced solid tumors
jRCT2031260634Phase 1Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of ABBV-253 in Nonhematologic neoplasms, sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events, Number of participants with abnormal change from baseline in clinical laboratory test results and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ABBV-253
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260634.